Published Date: 24-Nov-2022
Industry Insights | Market Trends | Highest number of Tables | 24/7 Analyst Support
According to a new report, published by KBV research, The Global Neurological Biomarkers Market size is expected to reach $4.0 billion by 2028, rising
According to a new report, published by KBV research, The Global Neurological Biomarkers Market size is expected to reach $12.9 billion by 2028, rising at a market growth of 14.2% CAGR during the forecast period.
The Proteomic market acquired maximum revenue share in the Global Neurological Biomarkers Market by Type in 2021; thereby, achieving a market value of $4.0 Billion by 2028. Due to the widespread use of proteomic biomarkers in neurological disorder research. Since denatured proteins or protein aggregates cause neurodegenerative disorders, proteomics is very helpful in understanding how these disorders arise.
The Parkinson’s Disease market is exhibiting a CAGR of 14.3% during (2022 - 2028). The second most prevalent neurodegenerative ailment is Parkinson's disease. Parkinson's disease patients have a gradual decline in motor function over time as a result of the death of dopamine-producing brain cells.
The North America market dominated the Global Neurological Biomarkers Market by Region in 2021; thereby, achieving a market value of $4.8 Billion by 2028. The Europe market is experiencing a CAGR of 13.7% during (2022 - 2028). Additionally, The Asia Pacific market would witness a CAGR of 15% during (2022 - 2028).
The market research report has exhaustive quantitative insights providing a clear picture of the market potential in various segments across the globe with country wise analysis in each discussed region. The key impacting factors of the market have been discussed in the report with the elaborated company profiles of F. HOFFMANN-LA ROCHE LTD., Bio-Rad Laboratories, Inc., Merck Group, PERKINELMER INC., Shimadzu corporation, Thermo Fisher Scientific, Inc., Quanterix Corporation, Neuro-Bio Ltd., BioMérieux S.A. and Myriad Genetics, Inc.
Unique Offerings from KBV Research